StockVS

Bullfrog AI Holdings, Inc. (BFRG) 주식 분석

의료

Bullfrog AI Holdings, Inc.

$0.71

+$0.05 (+8.26%)

최종 업데이트: 2026년 5월 26일

가격 추이

분석

회사 개요

Bullfrog AI Holdings, Inc. operates as a digital biopharmaceutical entity that leverages artificial intelligence and machine learning technologies to perform data analysis within the medical and healthcare sectors of the United States. The firm specifically markets bfLEAP, an analytical AI/ML platform designed to evaluate preclinical data sets, positioning itself at the intersection of technology and pharmaceutical research. This business falls under the Healthcare sector within the Health Information Services industry, suggesting a focus on data management and computational tools rather than traditional drug manufacturing or clinical service delivery. The company's current market capitalization stands at $19.18M, supported by total annual revenue of $116,670 and a workforce consisting of 9 employees. These valuation and operational metrics indicate that Bullfrog AI Holdings is a micro-cap entity with limited scale, operating in a niche segment where the disparity between market cap and revenue highlights the speculative nature often associated with early-stage technology-driven biopharmaceutical firms.

재무 건전성

The company reported a trailing twelve-month revenue of $116,670, while its net income for the same period was a loss of $6,498,068, and EBITDA registered a loss of $6,592,911. The substantial gap between the minimal revenue and the significant net loss reveals a cost structure where operating expenses, likely driven by high R&D or technology development costs, vastly exceed current revenue generation, which is typical for early-stage AI-focused biotech companies. Free cash flow for the trailing twelve months was negative at $3,317,732, indicating that the company is currently burning cash and lacks the immediate financial flexibility to fund operations without external capital injections. The gross margin stands at 18.8%, suggesting that while the cost of goods sold relative to revenue is controlled, the overall profitability model is not yet established. Conversely, the operating margin is reported as -5652.4% and the profit margin is 0.0%, figures that reflect extreme operational inefficiencies relative to revenue or accounting adjustments that result in losses far exceeding income. On the balance sheet, Bullfrog AI Holdings holds $2.18M in cash but carries $0 in debt, meaning the debt-to-equity ratio is effectively N/A due to the absence of liabilities. This cash position without debt suggests a conservative leverage strategy, yet the reliance on cash reserves to fund operations is critical given the current burn rate. The current ratio is 3.85, which indicates a strong short-term liquidity position where current assets significantly exceed current liabilities, providing a buffer against immediate solvency risks despite the operating losses. Furthermore, the return on equity is -183.0% and the return on assets is -98.6%, metrics that reveal management is currently destroying shareholder value and failing to generate returns on the capital base deployed in the business.

밸류에이션 평가

The trailing P/E ratio and forward P/E ratio are both listed as N/A, as the company is not currently profitable and therefore lacks the earnings necessary to calculate these standard multiples. The absence of a positive P/E implies that traditional earnings-based valuation models are inapplicable, shifting focus to alternative metrics for assessing the company's worth. The price-to-book ratio is 5.56, which indicates that the market is valuing the company at a significant premium over its net book value, a common occurrence in technology firms where intangible assets like AI platforms are not fully captured on the balance sheet. The price-to-sales ratio is 164.44, and the EV/EBITDA stands at -1.67, suggesting that the market is pricing in substantial future growth expectations or valuing the asset base despite current negative earnings power. The stock has traded within a 52-week range between a low of $0.42 and a high of $2.20, meaning the current price sits below the recent 52-week high, reflecting a correction from its peak performance levels. The beta value is -2.29, a highly unusual negative figure that suggests the stock's price volatility moves inversely to the broader market and exhibits extreme sensitivity to market fluctuations, making it a high-risk instrument for price movements.

Growth & Income

Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A due to the company's limited historical data or lack of profitability required to calculate meaningful growth percentages. Consequently, it is impossible to determine if earnings are growing faster or slower than revenue based on the available fiscal history, as the company has not yet achieved consistent positive earnings to establish a growth trajectory. The dividend yield is N/A and the payout ratio is 0.0%, indicating that the company does not distribute dividends to shareholders. This non-dividend status implies that Bullfrog AI Holdings reinvests all available earnings, or rather its remaining cash reserves, back into the business for research and development to pursue long-term growth rather than providing immediate income to investors. The overall growth and income profile for Bullfrog AI Holdings is characterized by a complete absence of current income generation and undefined growth rates, relying entirely on the successful execution of its AI platform to eventually achieve profitability and potential future capital appreciation.

동종업체 비교

Bullfrog AI Holdings, Inc. (BFRG) 은(는) 의료 정보 서비스 산업에서 운영됩니다. 시가총액 기준으로 가장 가까운 동종업체와의 비교는 다음과 같습니다:

기업명 티커 시가총액 PER
Bullfrog AI Holdings, Inc. BFRG $13.13M N/A
Veeva Systems Inc. VEEV $25.87B 29.1
BrightSpring Health Services, Inc. BTSG $11.70B 78.3
Tempus AI, Inc. TEM $8.38B N/A

의료 정보 서비스 산업 평균 PER은 57.5배입니다. Bullfrog AI Holdings, Inc.의 PER은 N/A입니다.

이 분석은 AI가 생성한 것으로 정보 제공 목적으로만 사용되며 투자 조언이 아닙니다. 데이터가 지연되거나 부정확할 수 있습니다. 투자 결정을 내리기 전에 항상 직접 조사하고 자격을 갖춘 재무 상담사와 상담하세요.

Bullfrog AI Holdings, Inc. 소개

Bullfrog AI Holdings, Inc. operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform to analyze preclinical and clinical data for biotechnology and pharmaceutical companies, and other organizations. It also develops BF-222, a novel formulation of mebendazole , which is in the first phase for the treatment of Glioblastoma; BF-223, a novel prodrug of mebendazole, which is in the preclinical stage for the treatment of Glioblastoma; and BF-114, which is in the discovery phase, to treat obesity and chronic liver diseases. The company has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. It has a partnership with the Lieber Institute for Brain Development (LIBD) to enable the discovery and development of precision treatments for CNS disorders. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.

회사 설명은 영어로 표시됩니다.

웹사이트 방문 →

주요 지표

시가총액
$13.13M
PER
N/A
52주 최고가
$2.04
52주 최저가
$0.42
평균 거래량
12.00M
베타
-3.00

데이터는 yfinance를 통해 Yahoo Finance에서 제공됩니다. 매일 업데이트.

기업 정보

거래소
NASDAQ
국가
United States
직원 수
9